Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 38 for your search:
Drug:
sirolimus
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-Based Immunosuppressive Protocol
Phase:
Phase IV
Type:
Prevention
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
PROSKIN 01
, NCT00866684
2.
TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 to 80
Sponsor:
Other
Protocol IDs:
2003.333
, NCT00133887
3.
Immunosuppression in Patients Undergoing Liver Transplantation for Hepatocellular Carcinoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SiLVER05
, EudraCT Number:, 2005-005362-36, NCT00355862
4.
Phase III Randomized Study of Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus and Methotrexate With or Without Sirolimus in Pediatric Patients With Intermediate-Risk or High-Risk Acute Lymphoblastic Leukemia in Second Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
1 to under 22 at first relapse
Sponsor:
NCI
Protocol IDs:
COG-ASCT0431
, ASCT0431, COG-PBMTC-ONCO51, NCT00382109
5.
Sirolimus-Based Immunosuppression Therapy in OLT for Patients With HCC Exceeding Milan Criteria
Phase:
Phase III
Type:
Supportive care
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
ZSH-LCI-FJ-0002
, NCT00554125
6.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
7.
Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
04-16
, NCT00409994
8.
Phase I/II Study of Erlotinib Hydrochloride and Sirolimus in Patients With Recurrent Malignant Glioma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
UCLA-0604104
, OSI3781s, NCT00509431
9.
Phase I/II Randomized Pilot Study of Targeted Immune-Depleting Chemotherapy, Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation from an HLA-Matched Unrelated Donor, and Graft-Versus-Host Disease Prophylaxis Comprising Tacrolimus, Methotrexate, and Sirolimus Versus Alemtuzumab and Cyclosporine in Patients With High-Risk Advanced Hematologic Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
10.
Phase I/II Study of Pemetrexed Disodium and Sirolimus in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0078
, 08-C-0078, NCI-P07207, NCT00636532
11.
Phase II Pilot Study of Induction Chemotherapy Followed By Allogeneic/Syngeneic Peripheral Blood Stem Cell Transplantation in Patients With High-Risk, Recurrent Pediatric Sarcoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
4 to 35
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0259
, NCT00047372
12.
Pilot Study of Donor Th2 Cells Generated In Vitro By Sirolimus Treatment With or Without Oral Sirolimus Versus Oral Sirolimus Alone For Prevention Of Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NCI-04-C-0055
, NCT00077480
13.
Phase II Randomized Study of Postgrafting Immunosuppression Comprising Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus to Prevent Acute Graft-Versus-Host Disease After Unrelated Donor Filgrastim (G-CSF)-Mobilized Peripheral Blood Mononuclear Cell Transplantation With Nonmyeloablative Conditioning in Patients With Hematologic Malignancies
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Any age
Sponsor:
Other
Protocol IDs:
FHCRC-1938.00
, 5887, NCT00105001
14.
A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
0605001396
, NCT00411788
15.
Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus Trial (The MILES Trial)
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
070037
, 07-H-0037, NCT00408343
16.
Phase II Study of Yttrium Y 90 Ibritumomab Tiuxetan, Indium In-111 Ibritumomab Tiuxetan, Rituximab, Fludarabine Phosphate, and Melphalan Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
CHNMC-05149
, 05149, NCT00577278
17.
Phase II Study of Graft-Versus-Host Prophylaxis Comprising Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin in Patients Undergoing Unrelated-Donor Hematopoietic Cell Transplantation For Hematological Malignancy
Phase:
Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
CHNMC-06141
, 06141, NCT00589563
18.
Phase II Pilot Study of Low-Intensity Chemotherapy Comprising Pentostatin and Cyclophosphamide Followed By Allogeneic Hematopoietic Stem Cell Transplantation and Donor Th2 Cell Infusions in Patients With Metastatic Renal Cell Carcinoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0088
, 08-C-0088, 8242, NCI-P07312, NCT00641485
19.
Phase II Study of Sirolimus in Patients With Inoperable Plexiform Neurofibromas Associated With Neurofibromatosis Type 1
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
3 and over
Sponsor:
NCI
Protocol IDs:
NF-102
, NF #102, NCI-08-C-0096, NCT00652990
20.
Phase II Pilot Study of Sirolimus, Tacrolimus, and Anti-Thymocyte Globulin as Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplantation
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
WSU-2007-127
, 2007-127, GENZ-WSU-2007-127, NCT00691015
21.
Phase II Pilot Study of Sirolimus in Patients With Cowden Syndrome or Other Syndromes Characterized by Germline Mutations in PTEN
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0151
, 08-C-0151, NCI-P07252, NCT00722449
22.
A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
16 and over
Sponsor:
Other
Protocol IDs:
UMCC 2008.049
, NCT00743509
23.
Phase II Study of Cytarabine, Methotrexate, Cyclophosphamide, Dexamethasone, Doxorubicin Hydrochloride, Vincristine (HCVAD) and Dasatinib With or Without Allogeneic Stem Cell Transplantation in Patients With Philadelphia Chromosome- and/or BCR/ABL-Positive Acute Lymphoblastic Leukemia
Phase:
Phase II
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Approved-not yet active
Age:
18 to 50
Sponsor:
NCI
Protocol IDs:
SWOG-S0805
, S0805, NCT00792948
24.
Phase I Study of Sirolimus in Pediatric Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
21 and under
Sponsor:
Other
Protocol IDs:
CHP-755
, CHP-IRB-2002-12-3086, NCT00068302
25.
Phase I Pilot Study of Anti-Thymocyte Globulin and Sirolimus in Patients With Relapsed Multiple Myeloma
Phase:
Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other, Pharmaceutical / Industry
Protocol IDs:
URCC-U11405
, GENZ-URCC-U11405, NCT00317798
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
